322 related articles for article (PubMed ID: 32480227)
1. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
Nimtrakul P; Tiyaboonchai W; Lamlertthon S
Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
[TBL] [Abstract][Full Text] [Related]
4. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
Jain S; Valvi PU; Swarnakar NK; Thanki K
Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.
Italia JL; Yahya MM; Singh D; Ravi Kumar MN
Pharm Res; 2009 Jun; 26(6):1324-31. PubMed ID: 19214716
[TBL] [Abstract][Full Text] [Related]
6. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
8. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations.
Jansook P; Pichayakorn W; Ritthidej GC
Drug Dev Ind Pharm; 2018 Oct; 44(10):1693-1700. PubMed ID: 29936874
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
[TBL] [Abstract][Full Text] [Related]
12. Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module.
Chaudhari MB; Desai PP; Patel PA; Patravale VB
Drug Deliv Transl Res; 2016 Aug; 6(4):354-64. PubMed ID: 26712123
[TBL] [Abstract][Full Text] [Related]
13. Mixed micellar nanoparticle of amphotericin B and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity.
Han K; Miah MA; Shanmugam S; Yong CS; Choi HG; Kim JA; Yoo BK
Arch Pharm Res; 2007 Oct; 30(10):1344-9. PubMed ID: 18038914
[TBL] [Abstract][Full Text] [Related]
14. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen.
Kang JY; Gao J; Shin DH; Alvarez C; Zhong W; Kwon GS
Pharm Nanotechnol; 2016; 4(1):16-23. PubMed ID: 27774409
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
[TBL] [Abstract][Full Text] [Related]
17. Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In Vitro Antifungal Activity.
Casa DM; Carraro TC; de Camargo LE; Dalmolin LF; Khalil NM; Mainardes RM
J Nanosci Nanotechnol; 2015 Jan; 15(1):848-54. PubMed ID: 26328449
[TBL] [Abstract][Full Text] [Related]
18. Design of Micelle Nanocontainers Based on PDMAEMA-b-PCL-b-PDMAEMA Triblock Copolymers for the Encapsulation of Amphotericin B.
Diaz IL; Parra C; Linarez M; Perez LD
AAPS PharmSciTech; 2015 Oct; 16(5):1069-78. PubMed ID: 25669917
[TBL] [Abstract][Full Text] [Related]
19. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
